Revolutionizing Cell Line Development with ProteoNic's New Platform
Revolutionizing Cell Line Development
ProteoNic has recently unveiled an exciting advancement in its offerings—the 2G UNic® transposon platform. This innovative platform is making waves within the biopharmaceutical sector, providing enhanced cell line productivity and streamlined usability. ProteoNic stands out as a key player in vector technology for biologics and gene therapy, setting the stage for significant developments in the industry.
Innovative Combination of Technology
The 2G UNic transposon platform merges the proven capabilities of ProteoNic’s 2G UNic vector technology with a unique transposon system. This strategic combination enables the creation of cell lines that boast superior productivity and stability while also reducing development timelines. This technology's versatility allows it to be applied across mammalian and yeast cell platforms, catering to a range of product classes. It opens doors for clients pursuing complex biologics and those struggling with difficult-to-express proteins.
Enhancing Current Offerings
In addition to launching the new platform, ProteoNic is expanding its existing 2G UNic vector technology to enhance third-party transposon systems. This upgrade empowers customers to optimize their established workflows with a premium vector backbone, significantly boosting performance for cell line generation, no matter the baseline platform. This flexibility positions ProteoNic as a vital resource for biopharma firms looking for innovative solutions.
Core Technology Driving Results
The heart of ProteoNic's methodology lies in its 2G UNic vector technology, renowned for its significant productivity gains. By effectively increasing the titers of complex biologics, this technology also contributes to a reduction in manufacturing costs. Now, its adaptability with transposon systems further maximizes client performance, regardless of cell type or product class.
Industry Impact and Events
The 2G UNic platform was showcased at a recent BioProcess International (BPI) event, part of Biotech Week Boston. This presentation emphasized its capability to bring substantial enhancements in productivity and development speed for complex biologics, demonstrating impressive results like more than double the production titers, reaching up to 10 g/L.
CEO Frank Pieper expressed pride in this launch, stating, "We are proud to announce the development and launch of our novel 2G UNic transposon platform that takes productivity, flexibility, and ease of use in cell line generation to the next level. By expanding our premium 2G UNic vector technology to support other transposon systems, we can now provide maximum flexibility to our clients." This exciting development underscores ProteoNic's commitment to innovation and excellence.
Opportunities in Biotechnology
The applications of the new transposon platform extend beyond traditional scopes, promising advancements in stable producer cell line generation for cell and gene therapy. This holds tremendous potential for partners operating within the diverse landscape of biopharmaceuticals, opening new avenues for collaboration and growth.
ProteoNic's launch reflects extensive verification processes with various industry partners and marks the full-scale launch of its commercially available 2G UNic transposon platform alongside upgraded vector technology for licensing. This strategic direction underscores the company's goal of driving advancements in biopharmaceutical manufacturing.
About ProteoNic
ProteoNic is a privately held enterprise dedicated to delivering premium technology and services aimed at enhancing biologics manufacturing. The proprietary 2G UNic technology provides top-notch solutions designed to improve gene expression in mammalian production systems. ProteoNic licenses its innovative technology globally to biopharmaceutical companies and CDMOs for use in therapeutic protein and gene therapy applications.
To learn more about ProteoNic and its commitments to advancing the field, visit www.proteonic.nl.
Media Contact
For further inquiries, please contact Jonathan Frampton, VP of Business Development. You can reach him via email at frampton@proteonic.nl.
Frequently Asked Questions
What is the 2G UNic transposon platform?
The 2G UNic transposon platform is a blend of advanced vector technology designed to enhance cell line productivity and minimize development timelines in biologics.
How does ProteoNic's technology improve productivity?
The technology significantly boosts titers of complex biologics, thereby reducing manufacturing costs and enhancing overall efficiency in production.
What are the applications of the new platform?
The platform is applicable across various sectors, including therapeutic antibody production, protein synthesis, and gene therapy, creating opportunities for enhanced production capabilities.
What recent event highlighted the 2G UNic platform?
The platform was featured at a BioProcess International event, showcasing its impressive productivity enhancements and development speed.
Who can benefit from ProteoNic's offerings?
Biopharmaceutical companies and contract development manufacturing organizations (CDMOs) can leverage ProteoNic's technology to enhance their production workflows and outcomes.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.